期刊文献+

中医药对非小细胞肺癌免疫调节作用研究进展 预览 被引量:1

Research Progress on Chinese Medicine for Immunoregulation of Non-small Cell Lung Cancer
在线阅读 下载PDF
收藏 分享 导出
摘要 中医药在改善非小细胞肺癌患者免疫功能方面的研究主要涉及细胞免疫部分,如T细胞亚群、自然杀伤细胞、白细胞介素-4、白细胞介素-13、转化生长因子-β、干扰素-γ及肿瘤相关巨噬细胞等,但还存在以下问题和不足:①临床研究样本量较小,大多数为单中心,个别研究并未设置对照组,缺乏令人信服的循证医学资料,可信度不高;②中医对肺癌的辨证分型尚未统一,疗效判定缺乏统一标准,影响中医药对肺癌的深入研究和学术交流;③大部分研究都是中医药结合化疗,缺乏单纯中医药治疗肺癌的研究报道;④对于中医药影响肺癌免疫功能的机制尚不明确。今后研究的主要内容:①由于不同患者间遣方用药存在差异性,故对中医药进行标准化研究还需要进一步探索;②中医药有关肿瘤免疫调节机制的研究以扶正类中医药为主,今后应加强清热解毒药、活血化瘀药、软坚散结药等在肿瘤免疫中的研究;③扩大中医药在肿瘤免疫调节中的研究范围;④应尽快统一中医证型,确立疗效标准,提高中医药研究科学性。 The research of Chinese medicine in improving the immune function of patients with non-small cell lung cancer mainly involves cellular immune parts,such as T cell subsets,natural killer cells,interleukin-4,interleukin-13,transforming growth factor-β,interferon-γ and tumor-associated macrophages and so on,but the following problems and deficiencies exist:(1)Clinical studies have small sample sizes,most of which are single-center. Individual studies do not have a control group,lacking convincing evidence-based medical data,and the credibility is not high;(2)The syndrome differentiation of lung cancer in Chinese medicine has not been unified,and there is no unified standard for efficacy judgment,which affects the in-depth study and academic exchange of Chinese medicine on lung cancer;(3)Most of the studies are Chinese medicine combined with chemotherapy,and there is no research report on the treatment of lung cancer by simple Chinese medicine;(4)The mechanism of Chinese medicine affecting the immune function of lung cancer is not clear. The main content of future research:(1)Due to the differences in the use of different patients,it is necessary to further explore the standardization of Chinese medicine;(2)The research on the mechanism of tumor immune regulation in Chinese medicine is mainly based on Chinese medicine of strengthening vital qi type. In the future,research on tumor immunity should be strengthened on Chinese medicine of clearing heat and removing toxicity,promoting blood circulation for removing blood stasis and softening and resolving hard mass;(3)Expand the scope of research on traditional Chinese medicine in tumor immune regulation;(4)The Chinese medicine syndrome type should be unified as soon as possible. The efficacy standard should be established and the scientific research of Chinese medicine should be improved.
作者 许荣忠 李雁 XU Rongzhong;LI Yan(Affiliated City Chinese Medicine Hospital to Shanghai University of Chinese Medicine,Oncology,Shanghai China 200071)
出处 《中医学报》 CAS 2019年第3期501-504,共4页 Journal of Henan University of Chinese Medicine
基金 国家自然科学基金面上项目(81473627) 上海市自然科学基金面上项目(14ZR1439000) 上海市卫生局重点项目(20134016) 上海市市级医院新兴前沿技术联合攻关项目(SHDC12014127) 上海中医药大学预算内项目(2014YSN57).
关键词 非小细胞肺癌 中医药 免疫调节 免疫功能 non-small cell lung cancer Chinese medicine immune regulation immune Function
作者简介 许荣忠(1990-),男,福建泉州人,医学硕士,研究方向:中医肿瘤学;通信作者:李雁(1961-),男,博士研究生导师,主任医师,研究方向:中医肿瘤学。Email:18916767226@163.com.
  • 相关文献

参考文献22

二级参考文献114

共引文献279

同被引文献37

引证文献1

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈